Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea.

ABSTRACT:

Background

Chimeric antigen receptor T-cell therapy represents a revolutionary advancement in personalized treatment for diffuse large B-cell lymphoma (DLBCL). However, data regarding the use of tisagenlecleucel (tisa-cel) outside of clinical trials remain scarce, especially in East Asia. Therefore, we conducted this study to provide insights into the logistics, efficacy, and safety profile of tisa-cel treatment in Korea.

Methods

Clinical data were collected from 46 patients with DLBCL who underwent leukapheresis for commercial tisa-cel manufacturing at Seoul National University Hospital between January 2022 and December 2023. Response evaluations were conducted at 1, 3, 6, and 12 months after tisa-cel infusion.

Results

Overall, 44 patients received tisa-cel infusion.

SUBMITTER: Kim DH 

PROVIDER: S-EPMC12722673 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature